Literature DB >> 14561999

Continued neurocognitive development and prevention of cardiopulmonary complications after successful BMT for I-cell disease: a long-term follow-up report.

S Grewal1, E Shapiro, E Braunlin, L Charnas, W Krivit, P Orchard, C Peters.   

Abstract

I-cell disease or mucolipidosis type II, a rare inherited storage disorder of lysosomal enzyme localization, is characterized by dysostosis multiplex, progressive severe psychomotor retardation and death by 5-8 years from congestive heart failure and recurrent pulmonary infections. A 19-month old girl with I-cell disease received a bone marrow transplant (BMT) from an HLA-identical carrier brother. At the age of 7 years, 5 years after BMT, she has no history of respiratory infections. Her cardiac function remains normal with a shortening fraction of 47%, and she continues to gain neurodevelopmental milestones, albeit at a very slow rate. Musculoskeletal deformities have worsened despite BMT. This is the first report describing neurodevelopmental gains and prevention of cardiopulmonary complications in I-cell disease after BMT.

Entities:  

Mesh:

Year:  2003        PMID: 14561999     DOI: 10.1038/sj.bmt.1704249

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  8 in total

Review 1.  Cell- and gene-based therapeutic approaches for neurological deficits in mucopolysaccharidoses.

Authors:  Dao Pan
Journal:  Curr Pharm Biotechnol       Date:  2011-06       Impact factor: 2.837

2.  Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome.

Authors:  Daren Wang; Wei Zhang; Theodosia A Kalfa; Gregory Grabowski; Stella Davies; Punam Malik; Dao Pan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-11-10       Impact factor: 11.205

3.  Bone marrow transplantation for feline mucopolysaccharidosis I.

Authors:  N Matthew Ellinwood; Marie-Anne Colle; Margaret A Weil; Margret L Casal; Charles H Vite; Staci Wiemelt; Christopher W Hasson; Thomas M O'Malley; Xingxuan He; Ulana Prociuk; Lucie Verot; John R Melniczek; Anne Lannon; Gustavo D Aguirre; Van W Knox; Sydney M Evans; Marie T Vanier; Edward H Schuchman; Steven U Walkley; Mark E Haskins
Journal:  Mol Genet Metab       Date:  2007-05-07       Impact factor: 4.797

4.  Co-expression of MGMT(P140K) and alpha-L-iduronidase in primary hepatocytes from mucopolysaccharidosis type I mice enables efficient selection with metabolic correction.

Authors:  Daren Wang; D Nicole Worsham; Dao Pan
Journal:  J Gene Med       Date:  2008-03       Impact factor: 4.565

5.  Outcomes after hematopoietic stem cell transplantation for children with I-cell disease.

Authors:  Troy C Lund; Sara S Cathey; Weston P Miller; Mary Eapen; Martin Andreansky; Christopher C Dvorak; Jeffrey H Davis; Jignesh D Dalal; Steven M Devine; Gretchen M Eames; William S Ferguson; Roger H Giller; Wensheng He; Joanne Kurtzberg; Robert Krance; Emmanuel Katsanis; Victor A Lewis; Indira Sahdev; Paul J Orchard
Journal:  Biol Blood Marrow Transplant       Date:  2014-07-10       Impact factor: 5.742

6.  Is hematopoietic stem cell transplantation a therapeutic option for mucolipidosis type II?

Authors:  Luise Sophie Ammer; Sandra Pohl; Sandra Rafaela Breyer; Charlotte Aries; Jonas Denecke; Anna Perez; Martin Petzoldt; Johanna Schrum; Ingo Müller; Nicole Maria Muschol
Journal:  Mol Genet Metab Rep       Date:  2021-01-14

7.  GNPTAB c.2404C > T nonsense mutation in a patient with mucolipidosis III alpha/beta: a case report.

Authors:  Chi-Chun Ho; Lilian Li-Yan Tsung; Kam-Tim Liu; Wing-Tat Poon
Journal:  BMC Med Genet       Date:  2018-09-12       Impact factor: 2.103

Review 8.  Mucolipidoses Overview: Past, Present, and Future.

Authors:  Shaukat A Khan; Saori C Tomatsu
Journal:  Int J Mol Sci       Date:  2020-09-17       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.